ArriVent BioPharma (ArriVent BioPharma) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Change In Inventory?

ArriVent BioPharma's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means ArriVent BioPharma's inventory stayed the same from Dec. 2023 to Mar. 2024 .

ArriVent BioPharma's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means ArriVent BioPharma's inventory stayed the same from Dec. 2022 to Dec. 2023 .

ArriVent BioPharma's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ArriVent BioPharma Change In Inventory Historical Data

The historical data trend for ArriVent BioPharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Change In Inventory Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Change In Inventory

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial				-	-	-	-	-

ArriVent BioPharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

ArriVent BioPharma (NAS:AVBP) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ArriVent BioPharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ArriVent BioPharma's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ArriVent BioPharma's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

ArriVent BioPharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma (ArriVent BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus

ArriVent Appoints Kristine Peterson to its Board of Directors

By Marketwired • 04-22-2024